[{"id":"9d3a2345-4750-430f-b35f-e0833cfd90c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06042569","created_at":"2023-09-18T14:40:16.409Z","updated_at":"2025-02-25T17:39:21.068Z","phase":"Phase 2","brief_title":"Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial","source_id_and_acronym":"NCT06042569","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 09/16/2024","start_date":" 09/16/2024","primary_txt":" Primary completion: 03/20/2028","primary_completion_date":" 03/20/2028","study_txt":" Completion: 03/20/2028","study_completion_date":" 03/20/2028","last_update_posted":"2025-01-29"},{"id":"0ce25812-d787-4958-871c-71452dd45f1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01446731","created_at":"2025-07-19T13:53:52.425Z","updated_at":"2025-07-19T13:53:52.425Z","phase":"Phase 2","brief_title":"Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer","source_id_and_acronym":"NCT01446731","lead_sponsor":"Inge Marie Svane","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2024-07-03"},{"id":"5ef966bd-a434-424a-a96e-8afc658d0dee","acronym":"ECOG-ACRIN EAZ171","url":"https://clinicaltrials.gov/study/NCT04001829","created_at":"2021-01-18T19:40:09.877Z","updated_at":"2025-02-25T13:52:56.517Z","phase":"Phase 2","brief_title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","source_id_and_acronym":"NCT04001829 - ECOG-ACRIN EAZ171","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 08/09/2019","start_date":" 08/09/2019","primary_txt":" Primary completion: 09/19/2023","primary_completion_date":" 09/19/2023","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2024-06-25"},{"id":"da3993b4-3224-43f3-abf3-1a2b44201eaf","acronym":"TINKS","url":"https://clinicaltrials.gov/study/NCT05634369","created_at":"2023-12-20T08:17:53.968Z","updated_at":"2024-07-02T16:34:37.915Z","phase":"Phase 1/2","brief_title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","source_id_and_acronym":"NCT05634369 - TINKS","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • dexamethasone • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-05"},{"id":"42d098db-7735-4ec6-beca-081467347e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254384","created_at":"2021-01-18T00:51:46.726Z","updated_at":"2024-07-02T16:35:01.822Z","phase":"Phase 1","brief_title":"Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery","source_id_and_acronym":"NCT00254384","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/05/2005","start_date":" 10/05/2005","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-05-23"},{"id":"130d64cc-8174-4099-9fdc-c77e00468d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003209","created_at":"2021-01-18T09:08:50.149Z","updated_at":"2024-07-02T16:35:02.395Z","phase":"Phase 3","brief_title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02003209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TILs","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"},{"id":"282de3d0-8f82-4895-a112-bc0353a05ae5","acronym":"NSABP B-30","url":"https://clinicaltrials.gov/study/NCT00003782","created_at":"2021-01-17T22:53:06.131Z","updated_at":"2024-07-02T16:35:13.405Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes","source_id_and_acronym":"NCT00003782 - NSABP B-30","lead_sponsor":"NSABP Foundation Inc","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 5351","initiation":"Initiation: 03/01/1999","start_date":" 03/01/1999","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2024-03-21"},{"id":"3de318f9-9b7c-41b4-acab-222319081456","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706962","created_at":"2021-01-29T07:21:45.355Z","updated_at":"2024-07-02T16:35:27.214Z","phase":"Phase 1","brief_title":"TH1902 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04706962","lead_sponsor":"Theratechnologies","biomarkers":" CD4","pipe":" | ","alterations":" SORT1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SORT1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sudocetaxel zendusortide (TH 1902)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-12-04"},{"id":"3d78b9c9-76dd-4802-b171-aa3cd7379f4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02290145","created_at":"2021-01-18T10:47:43.754Z","updated_at":"2024-07-02T16:35:28.309Z","phase":"Phase 2","brief_title":"Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","source_id_and_acronym":"NCT02290145","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression • CCND1 expression • CCND1-H","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND1 expression • CCND1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-11-22"},{"id":"cd6bbcee-c7e4-4f63-a4d9-478a5b04000b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06136988","created_at":"2023-11-19T12:16:11.097Z","updated_at":"2024-07-02T16:35:28.828Z","phase":"Phase 1/2","brief_title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","source_id_and_acronym":"NCT06136988","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Enshuxing (enlonstobart) • albumin-bound docetaxel (CPO100)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-11-18"},{"id":"051a4bc8-04e5-4737-bcfd-a0523396c212","acronym":"CLOVER","url":"https://clinicaltrials.gov/study/NCT03926091","created_at":"2021-01-18T19:18:46.048Z","updated_at":"2024-07-02T16:35:29.307Z","phase":"Phase 3","brief_title":"Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer","source_id_and_acronym":"NCT03926091 - CLOVER","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 2172","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-14"},{"id":"65af3a39-ef1d-49dc-a8f5-a6e260b5808e","acronym":"PEACE-1","url":"https://clinicaltrials.gov/study/NCT01957436","created_at":"2021-01-18T08:53:11.774Z","updated_at":"2024-07-02T16:35:29.880Z","phase":"Phase 3","brief_title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","source_id_and_acronym":"NCT01957436 - PEACE-1","lead_sponsor":"UNICANCER","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • zoledronic acid"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1173","initiation":"Initiation: 11/13/2013","start_date":" 11/13/2013","primary_txt":" Primary completion: 08/18/2021","primary_completion_date":" 08/18/2021","study_txt":" Completion: 12/01/2032","study_completion_date":" 12/01/2032","last_update_posted":"2023-11-08"},{"id":"84ae37b2-6f5c-4e7e-be94-a941521ec5e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05863325","created_at":"2023-05-18T14:04:44.124Z","updated_at":"2024-07-02T16:35:30.313Z","phase":"Phase 2","brief_title":"A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05863325","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • albumin-bound docetaxel (CPO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/27/2023","start_date":" 06/27/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-06"},{"id":"a1ae15dd-4d5a-483e-bbe7-101c04dab9bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560663","created_at":"2021-01-17T17:33:38.631Z","updated_at":"2024-07-02T16:35:35.263Z","phase":"","brief_title":"Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer","source_id_and_acronym":"NCT01560663","lead_sponsor":"Miguel Martín Jiménez","biomarkers":" HER-2 • BRCA","pipe":"","alterations":" ","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 415","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-09-29"},{"id":"2d77b89f-9e94-4467-9a6b-0431b0e2457d","acronym":"NEOEPICURE","url":"https://clinicaltrials.gov/study/NCT05981326","created_at":"2023-08-08T14:08:33.294Z","updated_at":"2024-07-02T16:35:40.711Z","phase":"","brief_title":"Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer Patients","source_id_and_acronym":"NCT05981326 - NEOEPICURE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2033","study_completion_date":" 04/01/2033","last_update_posted":"2023-08-08"},{"id":"5d026fe8-d742-497c-a382-293da41307d7","acronym":"GASTFOX","url":"https://clinicaltrials.gov/study/NCT03006432","created_at":"2021-01-18T14:47:16.487Z","updated_at":"2024-07-02T16:35:43.295Z","phase":"Phase 3","brief_title":"PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA","source_id_and_acronym":"NCT03006432 - GASTFOX","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 507","initiation":"Initiation: 12/19/2016","start_date":" 12/19/2016","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-07-12"},{"id":"650a3245-ab7f-45dc-abea-d78920524b59","acronym":"CADENCE","url":"https://clinicaltrials.gov/study/NCT02547987","created_at":"2021-01-18T12:19:44.573Z","updated_at":"2024-07-02T16:35:45.450Z","phase":"Phase 2","brief_title":"Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer","source_id_and_acronym":"NCT02547987 - CADENCE","lead_sponsor":"Mothaffar Rimawi","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR positive • ER negative + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR positive • ER negative + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 06/25/2019","primary_completion_date":" 06/25/2019","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-06-16"},{"id":"15bb5495-63c3-4f91-90ff-661a64580c8a","acronym":"ANZUP 1903","url":"https://clinicaltrials.gov/study/NCT04918810","created_at":"2021-06-10T02:52:49.041Z","updated_at":"2024-07-02T16:35:51.957Z","phase":"Phase 2","brief_title":"Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT04918810 - ANZUP 1903","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" GSTP1","pipe":"","alterations":" ","tags":["GSTP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-03-29"},{"id":"18969080-8eb0-4d96-a700-a81dd448f550","acronym":"SINTART2","url":"https://clinicaltrials.gov/study/NCT02099188","created_at":"2021-07-13T21:53:06.604Z","updated_at":"2024-07-02T16:35:53.438Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","source_id_and_acronym":"NCT02099188 - SINTART2","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"c76b2924-526d-4c0c-91ca-abc674c755d0","acronym":"SINTART 1","url":"https://clinicaltrials.gov/study/NCT02099175","created_at":"2021-07-13T21:53:06.298Z","updated_at":"2024-07-02T16:35:53.426Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","source_id_and_acronym":"NCT02099175 - SINTART 1","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"d710738e-a173-4d1b-82da-c2c6cf5f1bd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02598895","created_at":"2021-01-18T12:36:58.377Z","updated_at":"2024-07-02T16:36:00.277Z","phase":"Phase 2","brief_title":"Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway","source_id_and_acronym":"NCT02598895","lead_sponsor":"University of Washington","biomarkers":" BRCA1 • BRCA2 • BRIP1","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • BRCA2 biallelic inactivation","tags":["BRCA1 • BRCA2 • BRIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • BRCA2 biallelic inactivation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 01/26/2016","start_date":" 01/26/2016","primary_txt":" Primary completion: 09/14/2021","primary_completion_date":" 09/14/2021","study_txt":" Completion: 09/14/2021","study_completion_date":" 09/14/2021","last_update_posted":"2022-11-17"},{"id":"857d16d6-8ed3-42fa-80e9-b2774b9e65f2","acronym":"ELEGANT","url":"https://clinicaltrials.gov/study/NCT02549677","created_at":"2021-01-18T12:20:02.670Z","updated_at":"2024-07-02T16:36:01.777Z","phase":"Phase 4","brief_title":"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer","source_id_and_acronym":"NCT02549677 - ELEGANT","lead_sponsor":"Ruijin Hospital","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 294","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2022-10-27"},{"id":"31f3fde4-f95b-4ccd-974f-65efdebf03c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05461261","created_at":"2022-07-18T15:02:03.321Z","updated_at":"2024-07-02T16:36:02.004Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer","source_id_and_acronym":"NCT05461261","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" BRCA1 • BRCA2 • ATM • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • docetaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-10-24"},{"id":"f63fc555-27f3-4ad1-bc4b-ca48a145c8a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05027204","created_at":"2021-08-30T21:53:04.885Z","updated_at":"2024-07-02T16:36:02.491Z","phase":"Phase 1/2","brief_title":"A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)","source_id_and_acronym":"NCT05027204","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • albumin-bound docetaxel (CPO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 03/04/2022","start_date":" 03/04/2022","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-10-13"}]